Scientists offer new clues as to how overzealous neuronal firing may fuel synaptic loss in early Alzheimer's. In Science July 9, scientists led by Soyon Hong at University College London report that ...

Alzheimer’s researchers have long wished for better mouse models. That is now coming true. Scientists at the Jackson Laboratory in Bar Harbor, Maine, are cranking out numerous lines that express ...

Transferrin-receptor shuttles distribute antibody cargo throughout the parenchyma, steering clear of ARIA-provoking vascular amyloid. Trontinemab is enrolling Phase 3 for early AD, announces plans for ...

Buoyed by data crediting amyloid removal with ever-so-slightly slowed cognitive decline, many scientists are now optimistic about the prospects for anti-amyloid immunotherapy. Four “-mabs”—of the ...

Humanized TREM2 mice were created in a two-step process: First, researchers generated transgenic mice that carry BACs containing the common variant of human TREM2, including its regulatory elements.

With two anti-amyloid antibodies now in clinical use, improving the safety of these treatments is front and center on clinicians’ minds. In the year since lecanemab was approved by the Food and Drug ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

Iron is an essential nutrient, but like any good thing, too much of it may do harm. According to an autopsy study published February 18 in Molecular Psychiatry, people who had had dementia and ...

CAR-T cell therapy has practically become a household name, given its success in taking down blood cancers. The chimeric antigen receptors used in this type of cell therapy are designed to sic killer ...

Clinicians have started using blood tests of p-tau217, a marker of amyloid plaques, to help diagnose AD in routine patient care, not just research studies. Alas, at AD/PD 2026, held March 17-21 in ...

The Alzheimer’s field was rocked this week by allegations against Sylvain Lesné at the University of Minnesota, Minneapolis. Lesné stands accused of manipulating data images in multiple papers, ...

On donanemab, younger people with fewer tangles benefitted the most. On lecanemab, too, people with the fewest tangles improved most on CDR-SB. In the DIAN prevention trial, eight years of ...